Published in Pharma Investments, Ventures and Law Weekly, November 13th, 2005
Access sold its interest in Aphthasol, all OraDisc products, and all Residerm products. In addition, Uluru has licensed Access' nanoparticle hydrogel aggregate technology. Access received $8.7 million at the closing of the agreement and may receive up to $3.7 million within 12 months after closing, and will receive an additional $1 million within 24 months after closing. Additional payments of up to $7 million will be made upon the achievement of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.